AllYouCanTech

FCC Approves Starlink to Offer Emergency Cellular Service in Areas Impacted by Hurricanes

# FCC Grants Emergency Authority to Starlink and T-Mobile for Satellite-to-Phone Coverage in Hurricane Helene-Affected Areas

In a pivotal decision aimed at enhancing communication capabilities in areas hit by disasters, the Federal Communications Commission (FCC) has conferred **SpaceX’s Starlink** and **T-Mobile** with emergency special temporary authority (STA) to offer satellite-to-phone coverage in regions affected by **Hurricane Helene**. This emergency approval enables Starlink’s satellites to provide vital wireless communication services directly to mobile devices, ensuring that both citizens and emergency personnel in impacted zones can maintain connectivity during the emergency.

## Emergency Satellite Coverage in North Carolina

SpaceX, the company behind Starlink, revealed that its satellites are already operational, providing emergency notifications to cell phones across all carriers in **North Carolina**, one of the states affected by Hurricane Helene. Beyond delivering emergency alerts, SpaceX is also evaluating basic SMS capabilities for most mobile devices on the **T-Mobile network** in the area.

“Thanks to the emergency special temporary authority granted by the FCC, SpaceX and T-Mobile can activate Starlink satellites for direct-to-cell service to enhance coverage for cell phones in the Hurricane Helene-affected regions,” SpaceX stated in a release. “The satellites have been activated and are now sending out emergency alerts to cell phones on every network in North Carolina.”

While this emergency service provides crucial support for those affected by the hurricane, SpaceX has advised that the service is not yet suited for commercial use. “SpaceX’s direct-to-cell constellation has not been completely deployed, so all services will be provided on a best-effort basis,” the company explained.

## Monitoring Hurricane Milton

Alongside its efforts in North Carolina, SpaceX is diligently tracking **Hurricane Milton**, which poses a threat to **Florida**. The company has expressed that it stands ready to undertake similar emergency measures in Florida should the need arise. Ben Longmier, Senior Director of Satellite Engineering at SpaceX, affirmed this in a message on X (previously Twitter), saying, “We are also closely monitoring Hurricane Milton and are prepared to react in Florida.”

## Temporary Spectrum Authority and FCC Support

The FCC’s emergency authorization permits SpaceX to utilize its **Supplemental Coverage from Space (SCS)** in the **1910–1915 MHz** and **1990–1995 MHz** frequency bands, leased from T-Mobile. This spectrum is being utilized to deliver satellite-to-phone service in areas impacted by Hurricane Helene. Although the service is primarily active in North Carolina at this time, the FCC has indicated that the approval encompasses all regions affected by the hurricane.

In addition to granting temporary spectrum authority to SpaceX and T-Mobile, the FCC has embarked on various additional measures to support communication providers and public safety in disaster-stricken regions. The agency has implemented special temporary authorities and regulatory waivers to aid in maintaining and restoring communication services, facilitate emergency operations, and assist with search and rescue activities. These efforts are essential for ensuring that both first responders and community members can communicate efficiently during and following the hurricane.

The FCC has also temporarily lifted certain eligibility regulations for the **Lifeline program**, which offers reduced phone and broadband services to low-income individuals. This waiver aims to support individuals in disaster-affected regions in applying for and securing necessary communication services during recovery.

## Starlink’s Direct-to-Cell Capabilities

SpaceX’s Starlink service, historically focused on delivering broadband internet via a network of low-Earth orbit (LEO) satellites, started launching satellites with **direct-to-cell capabilities** in **January 2024**. These satellites are intended to provide cellular service in locations where traditional cell towers are scarce or unreliable, including remote areas or disaster zones.

Earlier this year, SpaceX showcased the potential of this technology by facilitating text message exchanges between T-Mobile phones through one of its Starlink satellites. This achievement represented a significant advancement towards the broader implementation of satellite-to-phone services, which could alleviate coverage deficiencies in regions where conventional cellular networks face limitations due to terrain, land-use policies, or other influences.

T-Mobile has been a crucial collaborator in this endeavor, and the company has shown enthusiasm about the possibilities of Starlink’s direct-to-cell service in enhancing its network coverage. “This service will assist in filling gaps in areas where we lack coverage because of terrain constraints, land-use limitations, and other issues,” T-Mobile stated.

## The Future of Satellite-to-Phone Communication

Although the current application of Starlink’s satellite-to-phone service is restricted to emergency scenarios, the technology holds significant potential for the future of global communication. Once fully operational, this service has the potential to transform how individuals maintain connectivity, especially in rural or disaster-prone regions where traditional cellular infrastructure is insufficient.

For the moment, efforts continue to prioritize immediate support for those affected by Hurricane Helene and to ensure that communication lines remain uninterrupted during the ongoing recovery initiatives. The collaboration between Space

Supreme Court Decides Not to Review Case, Ending Legal Fight Over Shkreli’s 5,000% Increase in Drug Prices

# The Conclusion of Martin Shkreli’s Legal Issues: Supreme Court Rejects Appeal Regarding Daraprim Price Increase

The extensive and contentious legal proceedings involving Martin Shkreli, the former pharmaceutical executive infamous for raising the cost of a crucial medication by 5,000 percent, have finally reached their conclusion. On Monday, the U.S. Supreme Court dismissed Shkreli’s request to challenge a lower court’s ruling mandating him to repay $64.6 million in profits derived from his price-hiking activities with **Daraprim**, a medication used for treating a potentially fatal parasitic illness.

This verdict signifies the end of a legal drama that has unfolded over several years and solidified Shkreli’s status as an emblem of corporate avarice within the pharmaceutical sector.

## The Daraprim Price Increase

The uproar erupted in 2015 when Shkreli, via his pharmaceutical firm **Vyera Pharmaceuticals** (previously referred to as **Turing Pharmaceuticals**), obtained the rights to Daraprim, a long-established drug primarily used for the treatment of **toxoplasmosis**. Toxoplasmosis is a parasitic infection that poses severe risks for individuals with weakened immune systems, including those with **HIV**, **cancer**, or recipients of **organ transplants**. It can also pose significant threats to infants if they become infected during gestation.

Prior to Shkreli’s takeover, the cost of a single Daraprim tablet fluctuated between $13.50 and $17.50. Yet, once Vyera took charge of the drug, the price surged to $750 per tablet overnight, representing a staggering 5,000 percent jump. This abrupt price escalation ignited indignation among the public, healthcare practitioners, and legislators, as it placed a vital, life-sustaining medication beyond the reach of numerous at-risk patients.

Shkreli’s unapologetic justification for the price increase only fueled further outrage. He claimed the price surge was a normative business approach in the pharmaceutical realm and that the resulting profits would be allocated towards research and development of new medications. However, his indifferent demeanor and public image—often showcased on social media—earned him the nickname “Pharma Bro” and turned him into a focal point for criticism.

## The Legal Repercussions

The price increase swiftly caught the scrutiny of federal regulators and prosecutors. In 2021, the **Federal Trade Commission (FTC)**, alongside seven state attorneys general, initiated a lawsuit against Shkreli, accusing him of conducting an illegal, anticompetitive scheme aimed at sustaining the inflated price of Daraprim and obstructing competition from entering the marketplace.

The lawsuit asserted that Shkreli and Vyera Pharmaceuticals partook in a “web of anticompetitive restrictions” that effectively barred generic drug makers from producing more affordable alternatives to Daraprim. This included limiting access to the drug’s active components and entering into exclusive supply agreements with distributors, rendering it nearly impossible for competitors to develop or market a generic version of the medication.

In January 2022, **U.S. District Court Judge Denise Cote** sided with the FTC and the state attorneys general, concluding that Shkreli’s conduct was “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote mandated Shkreli to return $64.6 million in profits he had accrued from the Daraprim scheme and prohibited him from participating in the pharmaceutical sector ever again.

## The Supreme Court’s Rejection

Following the district court’s determination, Shkreli attempted to appeal the decision, maintaining that the court had overreached its jurisdiction and that the penalties were overly harsh. However, his endeavors to overturn the judicial ruling were thwarted at every tier of the legal system. Ultimately, on Monday, the **U.S. Supreme Court** declined to entertain Shkreli’s appeal, effectively concluding his legal proceedings.

The Supreme Court’s dismissal of the case indicates that the lower court’s ruling remains intact, and Shkreli will be obliged to remit the $64.6 million in restitution. Furthermore, the lifetime prohibition on his participation in the pharmaceutical industry endures.

## A Wider Effect on the Pharmaceutical Sector

Shkreli’s case has generated significant consequences for the pharmaceutical industry and has reinvigorated discussions regarding drug pricing in the United States. His actions underscored the weaknesses in the system that enable pharmaceutical firms to exploit monopolies on essential medications and engage in price-gouging tactics.

In the aftermath of the Daraprim controversy, legislators and regulators have advocated for reforms to avert similar occurrences in the future. The **FTC** has also intensified its initiatives to combat anticompetitive practices within the pharmaceutical domain, with a particular emphasis on companies employing tactics akin to those used by Shkreli to impede competition and uphold artificially inflated drug prices.

**FTC Chair Lina M. Khan** commended the district court’s

Report: Initial Launch of M4-Equipped Macs, Featuring Compact Mac Mini, Scheduled for November 1 Debut

### M4 Macs: Anticipations for Apple’s Upcoming Collection

Apple fans and technology observers are keenly anticipating the next series of Mac introductions, with credible rumors indicating that the much-anticipated M4 Macs are imminent. A recent report from Bloomberg’s Mark Gurman suggests that Apple is planning to reveal the fresh M4-powered machines in late October, potentially launching some of the models on **November 1**. This schedule mirrors last year’s Halloween-themed introduction of the original M3 Macs, adding to the enthusiasm.

Nonetheless, not every item announced in October will be available on November 1. Sources within the industry propose that lower-tier models might arrive sooner, while high-performance configurations could be distributed later in the month. Let’s explore what we can look forward to with Apple’s forthcoming M4 Mac range.

—

### The M4 Chip: A New Chapter for Macs

Anticipated to take center stage, the M4 chip follows its unexpected introduction in the iPad Pro earlier this year. Apple’s proprietary silicon has revolutionized the landscape since the M1 chip’s launch, providing substantial performance enhancements and energy efficiency compared to Intel-powered Macs. The M4 is likely to uphold this pattern, offering even more robust computing power while ensuring outstanding battery life and thermal management.

### Anticipated Features of the M4 Mac Range

#### 1. **14- and 16-inch MacBook Pros**
The flagship laptops from Apple are due for an update, and the 14- and 16-inch MacBook Pros are likely to be among the first to showcase the capabilities of the M4 chip. These models will probably be available in three configurations:
– **M4**: The fundamental model, delivering solid performance for daily tasks and light professional activities.
– **M4 Pro**: A more advanced version designed for users who need enhanced processing capabilities for tasks such as video editing, software development, and 3D rendering.
– **M4 Max**: The premium model, tailored for intensive workflows like top-tier video production, machine learning, and other demanding tasks.

The fresh MacBook Pros are expected to maintain the same aesthetic as their M3 counterparts, with the emphasis placed on internal enhancements rather than external modifications.

#### 2. **24-inch iMac**
The 24-inch iMac is also anticipated to receive an M4 upgrade. This all-in-one desktop has been a preferred choice among creative professionals and home users alike, appreciated for its elegant design and robust performance. With the M4 chip, this model is likely to experience even greater performance, making it an appealing option for those seeking a desktop computer without the power demands of a Mac Studio or Mac Pro.

#### 3. **Mac mini**
One of the most captivating updates in the M4 lineup is the **Mac mini**, rumored to receive its first major design refresh in 14 years. The existing Mac mini, boasting an aluminum unibody design, has seen little change since 2010. However, the new M4 Mac mini is believed to be smaller and closer in size to an Apple TV box, while still incorporating an internal power supply—removing the necessity for a cumbersome external power brick.

The Mac mini lineup is projected to feature two variations:
– **Entry-level Mac mini**: Featuring the standard M4 chip, targeting users in need of a compact, economical desktop for routine tasks.
– **Higher-end Mac mini**: Equipped with the M4 Pro chip, this model will bridge the divide between the entry-level Mac mini and the more powerful Mac Studio, offering a blend of performance and value for professionals.

The Mac mini’s redesign and the integration of the M4 Pro chip position it as one of the most exciting offerings in this lineup, particularly for users desiring a robust desktop experience without the bulk or expense associated with a Mac Studio.

—

### The Importance of the M4 Macs

The launch of the M4 Macs holds substantial importance for various reasons. Firstly, it signifies Apple’s continued commitment to custom silicon, enabling the company to enhance performance, battery longevity, and thermal efficiency in ways unattainable with Intel-based systems. The M4 chip is anticipated to provide further advancements in these domains, rendering the new Macs swifter, more efficient, and more proficient than ever before.

Secondly, the M4 Macs will likely pave the way for upcoming innovations within Apple’s hardware ecosystem. With the M4 chip, Apple is expected to challenge the conventions of mobile and desktop computing, further narrowing the distinctions between devices like the MacBook Pro, iMac, and iPad Pro.

Lastly, the rumored redesign of the Mac mini is particularly significant. Long popular among users desiring a potent desktop within a compact framework, the new design could broaden its appeal to an even wider audience. By offering both an entry-level and a higher-end variant, Apple

Nobel Prize in Medicine Given for Findings Associated with MicroRNAs

**The Function of MicroRNAs in Cellular Control and Development: An Award-Worthy Revelation**

MicroRNAs (miRNAs) have surfaced as vital modulators of gene expression, occupying a pivotal position in the complex molecular frameworks that dictate cellular operations, growth, and pathologies. These diminutive, non-coding RNA entities, usually measuring 20-24 nucleotides in size, were initially identified in the early 1990s, yet their importance has expanded as scientists have probed further into their functions across a spectrum of organisms. The identification of miRNAs has transformed our comprehension of gene regulation, with their significance emphasized by their involvement in an array of biological mechanisms, ranging from embryonic development to the emergence of human ailments.

### The Identification of MicroRNAs: A Worldwide Quest

The exploration for miRNAs initiated with the discovery of two pivotal genes in *Caenorhabditis elegans*, a minute nematode frequently utilized in genetic studies. The genes, *lin-4* and *let-7*, were found to generate small RNA entities that regulated other gene expressions by attaching to messenger RNAs (mRNAs) and hindering their translation into proteins. This regulatory paradigm was unparalleled in previous knowledge and indicated the presence of a novel dimension of gene control.

Since that point, scientists have scoured genomes from numerous species, unveiling over 38,000 potential miRNA precursors and nearly 50,000 mature miRNAs. These entities are not limited to animals; they have also been found in plants, hinting at the likelihood that miRNAs may have originated from a common ancestor of all eukaryotic organisms. This opens up the intriguing conjecture that miRNAs existed in some of the earliest unicellular life forms, contributing to the development of intricate life.

### The Intricacies of MicroRNA Function

A particularly captivating feature of miRNAs is their capacity to regulate multiple genes at once. An individual miRNA can attach to several distinct mRNAs, affecting the expression of a diversity of genes. This adaptability enables miRNAs to refine gene expression in reaction to different cellular signals and environmental factors. However, this intricacy also complicates the prediction of miRNA mutation effects. While certain miRNA genes, such as *lin-4* and *let-7*, yield pronounced phenotypes when altered, countless others may exhibit subtle or perplexing outcomes. This phenomenon likely stems from the fact that miRNAs typically operate alongside other regulatory molecules, creating a redundancy that can obscure the impact of losing a single miRNA.

For instance, multiple miRNAs might bind to the same mRNA, ensuring that the absence of one miRNA does not entirely thwart gene regulation. This redundancy characterizes biological systems, where various control layers contribute to stability and avert catastrophic failures. Nevertheless, it also makes it difficult for researchers to identify the specific roles of individual miRNAs, especially in complex organisms like humans.

### Vital for Growth and Survival

In spite of the hurdles in miRNA research, substantial evidence supports their necessity for normal development in numerous organisms. A critical protein involved in the processing of miRNAs is Dicer, an enzyme responsible for cutting precursor miRNAs into their functional forms. For example, eliminating the gene that encodes Dicer in mice results in premature embryonic death, underscoring miRNAs’ essential roles in early developmental stages.

In more targeted scenarios, the absence of Dicer in particular cell types can lead to severe consequences. For instance, B cells, a variant of immune cells, struggle to mature when Dicer is absent from that lineage. In the nervous system, a Dicer knockout results in microcephaly (a condition characterized by an abnormally small brain) and diminished branching of neuronal connections, culminating in early mortality. These observations highlight the significance of miRNAs in molding the growth and operation of various tissues and organs.

### MicroRNAs and Human Illness

Considering their fundamental role in gene expression regulation, it is perhaps predictable that miRNAs are associated with a wide spectrum of human diseases. Alterations in miRNA genes can cause dysregulation of essential pathways, contributing to issues such as cancer, cardiovascular diseases, and neurodegenerative conditions. For instance, specific miRNAs are recognized to function as tumor suppressors, hindering the unregulated cell proliferation that leads to cancer. When these miRNAs are mutated or absent, cells may evade standard regulatory mechanisms and grow uncontrollably.

The Nobel Committee has acknowledged miRNAs’ significance in human health, highlighting several genetic disorders that arise from mutations in miRNA genes. These revelations have paved the way for new strategies in therapy, with researchers investigating the potential of miRNA-centric treatments to rectify gene expression abnormalities in various diseases.

### A Novel Domain in Molecular Biology

The investigation of miRNAs has unveiled just how intricate life is at the cellular scale. While every cell must produce a fundamental array of genes to endure, the remainder of the genome